These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37999122)

  • 1. Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.
    Gozdz A
    Curr Oncol; 2023 Nov; 30(11):9676-9688. PubMed ID: 37999122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
    Manton CA; Johnson B; Singh M; Bailey CP; Bouchier-Hayes L; Chandra J
    Sci Rep; 2016 Jan; 6():18953. PubMed ID: 26804704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
    Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
    Pak O; Zaitsev S; Shevchenko V; Sharma A; Sharma HS; Bryukhovetskiy I
    Prog Brain Res; 2021; 266():195-209. PubMed ID: 34689859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
    Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
    Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
    Johansson P; Krona C; Kundu S; Doroszko M; Baskaran S; Schmidt L; Vinel C; Almstedt E; Elgendy R; Elfineh L; Gallant C; Lundsten S; Ferrer Gago FJ; Hakkarainen A; Sipilä P; Häggblad M; Martens U; Lundgren B; Frigault MM; Lane DP; Swartling FJ; Uhrbom L; Nestor M; Marino S; Nelander S
    Cell Rep; 2020 Jul; 32(2):107897. PubMed ID: 32668248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
    Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
    Huang J; Campian JL; Gujar AD; Tran DD; Lockhart AC; DeWees TA; Tsien CI; Kim AH
    J Neurooncol; 2016 Jun; 128(2):259-66. PubMed ID: 26966095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
    Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
    Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition for the treatment of glioblastoma.
    Roth P; Mason WP; Richardson PG; Weller M
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1133-1141. PubMed ID: 32746640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
    Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
    J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
    Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
    Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.